Transparency and the Food and Drug Administration—A Quantitative Study

Ragnar Lofstedt King's Centre for Risk Management, Department of Geography, King's College London, London, United KingdomCorrespondence[email protected]

Frederic Bouder Department of Technology and Society Studies, Maastricht University, Maastricht, The Netherlands

Sweta Chakraborty Centre for Socio-Legal Studies, University of Oxford, Oxford, United Kingdom

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Ragnar Lofstedt. (2019) Transparency at the Swedish Forest Agency: What does the evidence show?. Journal of Risk Research 22:6, pages 701-716.
Read now

Dominic Way, Frederic Bouder, Ragnar Löfstedt & Darrick Evensen. (2016) Medicines transparency at the European Medicines Agency (EMA) in the new information age: the perspectives of patients. Journal of Risk Research 19:9, pages 1185-1215.
Read now

Ragnar Löfstedt, Dominic Way, Frederic Bouder & Darrick Evensen. (2016) Transparency of medicines data and safety issues–a European/US study of doctors’ opinions: what does the evidence show?. Journal of Risk Research 19:9, pages 1172-1184.
Read now

Ragnar Löfstedt & Dominic Way. (2016) Transparency and trust in the European pharmaceutical sector: outcomes from an experimental study. Journal of Risk Research 19:9, pages 1082-1103.
Read now

Ragnar Lofstedt. (2014) A possible way forward for evidence-based and risk-informed policy-making in Europe: a personal view. Journal of Risk Research 17:9, pages 1089-1108.
Read now

Articles from other publishers (3)

Åsa Boholm. (2019) Risk Communication as Government Agency Organizational Practice. Risk Analysis 39:8, pages 1695-1707.
Crossref

Dominic Way, Hortense Blazsin, Ragnar Löfstedt & Frederic Bouder. (2016) Pharmaceutical Benefit–Risk Communication Tools: A Review of the Literature. Drug Safety 40:1, pages 15-36.
Crossref

Frederic Bouder, Dominic Way, Ragnar Löfstedt & Darrick Evensen. (2015) Transparency in Europe: A Quantitative Study. Risk Analysis 35:7, pages 1210-1229.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Transparency and the Food and Drug Administration—A Quantitative Study

Articles from other publishers (3)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Transparency and the Food and Drug Administration—A Quantitative Study

Citations (8)

Read on this site (5)

Articles from other publishers (3)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date